Drug development in Alzheimer's disease: the contribution of PET and SPECT

• Hoofdauteurs: Lieven Denis Herwig Declercq (Auteur), Rik eVandenberghe (Auteur), Koen eVan Laere (Auteur), Alfons eVerbruggen (Auteur), Guy eBormans (Auteur)
• Formaat: Boek
• Gepubliceerd in: Frontiers Media S.A., 2016-03-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

Clinical trials aiming to develop disease-altering drugs for Alzheimer's disease (AD), a neurodegenerative disorder with devastating consequences, are failing at an alarming rate. Poorly defined inclusion- and outcome criteria, due to a limited amount of objective biomarkers, is one of the majo...